Controlled trial of thymostimulin and adenine arabinoside monophosphate for type B hepatitis
- Book ID
- 122770559
- Publisher
- Elsevier Science
- Year
- 1987
- Tongue
- English
- Weight
- 70 KB
- Volume
- 5
- Category
- Article
- ISSN
- 0168-8278
No coin nor oath required. For personal study only.
π SIMILAR VOLUMES
Six patients with chronic type B hepatitis were treated with adenine arabinoside 5'-monophosphate at a dosage of 10 to 15 mg per kg per day for 10 days. All demonstrated an immediate and marked decrease in serum hepatitis B virus DNA and DNA polymerase, and 5 of the 6 became negative for both marker
Ten patients with chronic type B hepatitis were treated with three courses of adenine arabinoside monosphosphate (Ara-AMP). The drug was given intramuscularly at a dosage of 10 mg/kg/day in ten-day courses during each of three sequential months. The patients were all men, aged 31-61 years, who were
Twenty-two heterosexuals and 2 1 homosexuals with chronic active hepatitis B and who had HBsAg, HBeAg and hepatitis B virus DNA in serum were randomized separately to receive adenine arabinoside monophosphate or placebo. In the 10 heterosexuals and nine homosexuals who received placebo, no change in